A new study finds that with the right patient engagement tools, clinicians can increase HPV immunization rates among teens.
Another day, another study on the potentially life-saving impact of vaccines. This time it’s a new study on the vaccine against human papillomavirus, or HPV, a sexually transmitted disease that can lead to cervical cancer. Earlier this week, researchers announced that since the vaccine came on the scene, rates of HPV among young women in the U.S. have plummeted.
In a perfect example of how the Affordable Care Act is broadening access to relatively low-cost and potentially life-saving interventions, a new study finds that the health reform law likely led more than 1 million young women to seek out the human papillomavirus vaccine and protect themselves against cervical cancer.
When the U.S. Food and Drug Administration approved the first vaccine to protect against cancers caused by certain strains of the human papillomavirus, or HPV, public health advocates cheered its life-saving potential. Unfortunately, the new vaccine quickly became embroiled in a debate over whether immunizing young girls against HPV, a sexually transmitted disease, would lead to risky sexual behavior.
Next time someone asks you what exactly public health does, repeat this number: 4.3 million. That’s the number of women — mothers, sisters, wives, aunts, grandmothers, daughters and friends — who might have otherwise gone without timely breast and cervical cancer screenings if it weren’t for public health and its commitment to prevention.